June 23, 2013
(NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data at the 73
Scientific Sessions of the American Diabetes Association (ADA) from
During a poster presented
Sunday, June 23
at 11:30 a.m. CT, researchers from
Medical Center demonstrate that the novel Lipoprotein Insulin Resistance score (LP-IR), which was developed by LipoScience, is a potentially clinically useful and convenient index of insulin resistance.
"Insulin resistance is accompanied by alterations in lipoprotein metabolism that result in distinct changes in the lipoprotein profile detected by NMR," explained lead investigator
, M.D, Professor of Cardiology at
and an author of the study. "These data support the LP-IR score, which combines six lipoprotein subclasses and size variables into a single parameter that could serve as a surrogate marker of insulin resistance."
Dr. Kraus and colleagues compared the LP-IR score, with values ranging from 0 (most insulin-sensitive) to 100 (most insulin-resistant), to two standard measures of insulin resistance – one derived from intravenous glucose tolerance tests and the other from the homeostatic model assessment of insulin resistance (HOMA-IR) – in two distinct cohorts of overweight and obese adults. The researchers concluded that the LP-IR score may provide a particularly efficient and effective way to identify insulin-resistant patients who are at increased risk of developing diabetes, so that they might receive the benefit of targeted lifestyle or other interventions.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the
test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million
tests have been ordered. LipoScience's automated clinical analyzer, Vantera
, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company's plans for potential future diagnostic tests. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Further information on potential factors and other risks that could affect the Company's business and operating results is included in the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2013
and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at
. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.